SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

27 Oct 2023 Evaluate
The company witnessed a 12.37% growth in the revenue at Rs. 46647.20 millions for the quarter ended September 2023 as compared to Rs. 41512.70 millions during the year-ago period.Net Profit recorded in the quarter ended September 2023 rise to 46.02% to Rs. 10296.90  millions  compared to R. 7051.90 millions in corresponding previous quarter.Operating profit for the quarter ended September 2023 rose to 15842.10 millions as compared to 11533.30 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 46647.20 41512.70 12.37 89829.10 79974.10 12.32 157906.00 153808.20 2.66
Other Income 2050.90 922.80 122.25 3630.70 2099.60 72.92 4567.90 6667.00 -31.48
PBIDT 15842.10 11533.30 37.36 29468.80 22646.50 30.13 42493.70 43779.30 -2.94
Interest 78.00 75.00 4.00 81.10 97.10 -16.48 270.20 269.30 0.33
PBDT 15764.10 11458.30 37.58 29387.70 22549.40 30.33 40364.50 43510.00 -7.23
Depreciation 1798.10 1760.10 2.16 3157.60 3043.70 3.74 5959.10 5466.20 9.02
PBT 13966.00 9698.20 44.01 26230.10 19505.70 34.47 34405.40 38043.80 -9.56
TAX 3669.10 2646.30 38.65 6983.00 5150.50 35.58 9710.10 9218.00 5.34
Deferred Tax -13.00 -6.00 116.67 -102.50 -95.30 7.56 -400.90 -276.90 44.78
PAT 10296.90 7051.90 46.02 19247.10 14355.20 34.08 24695.30 28825.80 -14.33
Equity 1614.70 1614.00 0.04 1614.70 1614.00 0.04 1614.30 1613.60 0.04
PBIDTM(%) 33.96 27.78 22.24 32.81 28.32 15.85 26.91 28.46 -5.46

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×